MAPT and Alzheimer disease: Another recent study also illustrated that (18F)MK-6240 PET could differentiate between AD and FTD, with patterns of (18F)MK-6240 uptake in line with Braak’s histopathological staging of tau pathology in AD and negligible (18F)MK-6240 uptake in FTD supporting the specificity of this PET tracer for tau tangle conformations [148].